Mirati Therapeutics / Credit: AP Images
Mirati team demonstrates that their KRAS G12C drug is active in NSCLC — but how do they stack up next to Amgen?
We have ourselves a horse race to watch in KRAS G12C, but it’s going to be awfully hard to call at this very early stage …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
